Elanco Animal Health Inc business relationships
Companies named in Elanco Animal Health Inc’s 10-K filed 2026-02-24, and public companies whose annual reports name Elanco Animal Health Inc. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 6.7 / 10
- AI naming
- 100 / 100 Top 1% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Named in Elanco Animal Health Inc’s annual report 4
“Rights to qualifying royalties sold to Blackstone apply to net sales of XDEMVY in the U.S. from April 1,” SEC filing
“Rather, Blackstone is only entitled to receive the qualifying royalties and milestones based on XDEMVY's net sales, as outlined within our license agreement with Tarsus.” SEC filing
“Our largest customer, an affiliate of Cencora, Inc., is a third-party veterinary distributor and represented approximately 12% of our total revenue in 2025.” SEC filing
“...the U.S. of XDEMVY ® (lotilaner ophthalmic solution) 0.25 % , a medical treatment for Demodex blepharitis in humans, by Tarsus Pharmaceuticals, Inc. (Tarsus) and (b) certain future sales milestone payments we are owed based on global net sales of XDEMVY, both of which are pursuant to the terms of a...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.